选择性和新型纤维细胞生长因子受体抑制剂作为潜在的抗癌模式的全面概述
Nem Kumar Jain1,2, Mukul Tailang2, Neelaveni Thangavel3
1School of Pharmacy, ITM University Gwalior 474001, Madhya Pradesh, India.
Acta pharmaceutica (Zagreb, Croatia)
|March 30, 2024
概括
纤维细胞生长因子受体 (FGFR) 抑制剂正在促进罕见和先进的FGFR驱动癌症的癌症治疗. 已批准的FGFR抑制剂在治疗胆管癌和髓状/淋巴状瘤方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 综合性基因组测序揭示了晚期癌症中纤维细胞生长因子受体 (FGFR) 基因的频繁变化.
- 这些遗传异常常见于对化学疗法和手术等传统疗法耐药的罕见癌症.
研究的目的:
- 审查已批准的纤维细胞生长因子受体氨酸激酶抑制剂 (FGFR-TKI) 的临床进展,安全性和疗效.
- 要突出正在进行的临床研究的FGFR抑制剂对其他FGFR驱动的恶性瘤.
主要方法:
- 对FGFR抑制剂的临床试验数据和FDA批准的适用情况的审查.
- 已批准的FGFR-TKI的安全性和有效性概况的分析.
主要成果:
- 四种FGFR抑制剂 (erdafitinib, pemigatinib, infigratinib, futibatinib) 已被FDA批准用于特定的FGFR驱动的癌症.
- 佩米加替尼 (pemigatinib) 已批准用于治疗具有FGFR变异的胆管癌和髓状/淋巴状瘤.
- 富提巴提尼布是第一类不可逆转的泛FGFR抑制剂,已被批准用于具有FGFR2异常的肝内胆固醇癌.
结论:
- FGFR抑制剂代表了针对特定瘤性FGFR驱动癌症的向治疗的重大进展.
- 目前正在进行的试验正在将FGFR抑制剂的治疗应用扩展到更广泛的恶性瘤中.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Introduction to Fibroblasts
3.1K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
